The antimicrobial activity (the ability to activate the microbial autolytic system) and immunostimulatory activity (the ability to improve the phagocytic cell functioning) of 20 food-protein hydrolysates [five food proteins (casein, alpha-lactalbumin, beta-lactoglobulin, ovalbumin and serum albumin) hydrolyzed with four gastrointestinal proteinases (trypsin, alpha-chymotrypsin, pepsin and pancreatin)] were examined. All the food-protein hydrolysates acted antimicrobially in vitro towards all 24 microbial strains tested: autolysis of 20 naturally autolyzing strains was activated, with the autolysis activation index (K(A)) ranging from 1.04 to 22.0, while autolysis was induced to values of 2.81-56.7% in four naturally nonautolyzing strains. When given to mice per os, all the food-protein hydrolysates enhanced the phagocytosing capacity of peritoneal macrophages, with the enhancement index (K(I)) ranging from 1.02 to 1.41. A direct correlation between K(A) and K(I) was observed. We make the presumption that K(I) is a function of K(A).

As Clostridium perfringens hyaluronidase has cell‐bound enzyme features, an enzymatic approach has been designed to facilitate the release of hyaluronidase into culture through increasing the clostridial cell wall permeability. As a result of the application of lytic peptidase from Actinomyces rutgersensis,β‐N‐acetylglucosaminidase and β‐N‐acetylmuramidase (both from Bacillus subtilis) commercially available preparations at the end of the producer's exponential growth phase, a 5·3‐, 4·8‐ and 4·0‐fold acceleration, respectively (but no enhancement), of hyaluronidase production in the course of batch cultivation of Cl. perfringens has been achieved. This also resulted in an approximately 10‐fold reduction in undesirable side lecithinase activity irrespective of the bacteriolytic enzyme preparation used.

No abstract

Polyferm and Fermosorb are oral acid resistant antimicrobial enzyme preparations designed specifically for therapy/prophylaxis of intestinal infections in animal neonates. Both are authorized for use throughout the former Soviet Union, but until now only Fermosorb is being applied on a large scale. The comparative studies on these two preparations, described in this paper, were carried out in order to find differences between the preparations. Characteristics that were compared included stability of the preparations in acidic environment as well as in storage (in vitro studies), and their efficacy for the treatment and prophylaxis of colibacillosis in newborn calves (in vivo studies). Results of in vitro studies revealed that proteolytic enzymes of Polyferm (as well as lytic enzymes of Fermosorb) were suitably (and in a very similar magnitude) protected from the influence of the acidic environment. The complete enzyme activity retention period in storage at room temperature of Polyferm and Fermosorb was equally high (5 years). In vivo studies performed on 2000 calves revealed that both preparations were highly effective and, although the efficacy of Polyferm was a bit lower than that of Fermosorb (93.6% vs. 95.0%, 94.6% vs. 95.8% for therapy and prophylaxis of colibacillosis, respectively), no statistically significant differences in the number of Polyferm vs. Fermosorb cured/protected animals were found. It is concluded that there were no reasons, other than the lack of supportive advertising materials, that might impede the utility of Polyferm.